MedTrace Logo

A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets

NCT07652047 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-06-17

No results posted yet for this study

Summary

A multi-center, randomized, placebo-controlled, double-blinded (within cohorts), Sponsor-unblinded, Phase 1b study to explore the safety, pharmacokinetics, and pharmacodynamics of CX11 tablets in participants with obesity or overweight with weight-related comorbidities.

Conditions

  • Obesity & Overweight

Interventions

DRUG

CX11

CX11 tablets administered orally once daily (QD) with meals

OTHER

Placebo

Matching placebo tablets administered orally once daily (QD) with meals

DRUG

CX11

CX11 tablets administered orally once daily (QD) with high fat, high calorie meal

Sponsors & Collaborators

  • Corxel Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-11
Primary Completion
2027-03-31
Completion
2027-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07652047 on ClinicalTrials.gov